Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Anaprazole Sodium in Reflux Esophagitis
NCT05604261Phase 2Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Anaprazole in reflux esophagitis (3 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoint: Endoscopic healing rate of reflux esophagitis at 8 weeks. Status: unknown.
02
Drugs
Anaprazole
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT05604261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604261.